A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control ...

University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity ...

A new USC Schaeffer Center white paper finds expanded access to anti-obesity medications would lead to significant increases ...

India must note that obesity is a public health challenge, waiting for holistic, multipronged and comprehensive interventions ...

A large majority of older Americans feel that health insurance – including Medicare – should cover anti-obesity medications, according to a new University of Michigan study.

covering them would financially benefit the state in the long term by reducing the cost of chronic diseases associated with ...

WalletHub released a new analysis ranking America's most overweight cities, based on obesity rates, health consequences and ...

Obesity “wonder drug” Wegovy is expected to be on sale in Ireland in the next 10 days but, even now, the woman charged with overseeing new product launches of the drug’s developer, Novo ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a ...